title: Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era.
abstract: Immunoglobulin A nephropathy (IgAN) frequently recurs in patients after renal transplantation (RT) on a conventional regimen of immunosuppressive therapy, but little is known about the influence of cyclosporine (Cs) on such a recurrence. We studied 84 patients retrospectively who underwent RT for renal failure attributable to IgAN (n = 71) or Henoch-Schönlein purpura nephropathy (HSPN) (n = 13) in two transplantation units, between January 1985 and June 1991 and were treated with Cs. Four patients died 3 months to 8 years after RT. Graft survival was 88% at 1 year, 75.2% at 5 years, and 63% at 8 years. Fifty patients underwent at least one graft biopsy, but studies with immunofluorescence were performed on only 28 (23 IgAN and 5 HSPN). After a mean follow-up of 68.1 +/- 37.2 months, mesangial IgA deposits recurred in 13 of the 28 patients (12 IgAN and 1 HSP) (prevalence, 46.4%). Among the 13 patients with recurrence of IgA deposits, all but 4 had urinary abnormalities. Light microscopy showed mesangial deposits and focal and segmental glomerular changes in 9 cases. Four patients lost their graft function 69 to 119 months after RT, and 2 had severe graft dysfunction. The rates of graft failure and mean serum creatinine at 1, 5, and 8 years were similar in the 13 patients with recurrence and the 15 patients without proven recurrence. In conclusion, Cs did not reduce the incidence or severity of IgAN recurrence. The latter was the cause of graft loss or dysfunction in 46.1 % of the patients with recurrent IgA deposits. Recurrent glomerulonephritis did not influence the 8-year graft survival in patients with IgAN or HSPN, but it may be an important cause of graft loss as evidenced by more extended follow-up.
authors.affiliation: Department of Nephrology, University Hospital of Nancy, France.
authors.forename: M
authors.initials: M
authors.lastname: Kessler
authors.forename: C
authors.initials: C
authors.lastname: Hiesse
authors.forename: D
authors.initials: D
authors.lastname: Hestin
authors.forename: D
authors.initials: D
authors.lastname: Mayeux
authors.forename: K
authors.initials: K
authors.lastname: Boubenider
authors.forename: B
authors.initials: B
authors.lastname: Charpentier
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000453:epidemiology* / Q000276:immunology / Q000601:surgery*; D006085:Graft Survival; D006801:Humans; D011695:IgA Vasculitis / Q000453:epidemiology / Q000276:immunology / Q000601:surgery; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007668:Kidney / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine